Literature DB >> 3287617

Retroviruses.

H Varmus1.   

Abstract

First brought to scientific attention as infectious cancer-causing agents nearly 80 years ago, retroviruses are popular in contemporary biology for many reasons. (i) The virus life cycle includes several events--in particular, reverse transcription of the viral RNA genome into DNA, orderly integration of viral DNA into host chromosomes, and utilization of host mechanisms for gene expression in response to viral signals--which are broadly informative about eukaryotic cells and viruses. (ii) Retroviral oncogenesis usually depends on transduction or insertional activation of cellular genes, and isolation of those genes has provided the scientific community with many of the molecular components now implicated in the control of normal growth and in human cancer. (iii) Retroviruses include many important veterinary pathogens and two recently discovered human pathogens, the causative agents of the acquired immunodeficiency syndrome (AIDS) and adult T cell leukemia/lymphoma. (iv) Retroviruses are genetic vectors in nature and can be modified to serve as genetic vectors for both experimental and therapeutic purposes. (v) Insertion of retroviral DNA into host chromosomes can be used to mark cell lineages and to make developmental mutants. Progress in these and other areas of retrovirus-related biology has been enormous during the past two decades, but many practical and theoretical problems remain to be solved.

Entities:  

Mesh:

Year:  1988        PMID: 3287617     DOI: 10.1126/science.3287617

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  131 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector.

Authors:  Shuji Kubo; Kohnosuke Mitani
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Tissue-type plasminogen activator gene targets thrombolysis in atriums.

Authors:  Yongsheng Gong; Fajiu Wang; Xia Li; Zhixin Gao; Kailun Zhang; Chen Fan; Xingen Liu
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

4.  Selection of retroviral reverse transcription primer is coordinated with tRNA biogenesis.

Authors:  Nathan J Kelly; Matthew T Palmer; Casey D Morrow
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  Translation of the rat LINE bicistronic RNAs in vitro involves ribosomal reinitiation instead of frameshifting.

Authors:  H Ilves; O Kahre; M Speek
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

7.  Recognition efficiency of the hepatitis B virus polyadenylation signals is tissue specific in transgenic mice.

Authors:  S Perfumo; L Amicone; S Colloca; M Giorgio; L Pozzi; M Tripodi
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced.

Authors:  X B Lu; J Heimer; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  Age-dependent poliomyelitis of mice: expression of endogenous retrovirus correlates with cytocidal replication of lactate dehydrogenase-elevating virus in motor neurons.

Authors:  C H Contag; P G Plagemann
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  Retrovirus infection: effect of time and target cell number.

Authors:  J R Morgan; J M LeDoux; R G Snow; R G Tompkins; M L Yarmush
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.